Outlook Therapeutics Inc Stock Current Valuation
| OTLK Stock | USD 2.01 0.31 18.24% |
Valuation analysis of OUTLOOK THERAPEUTICS INC helps investors to measure OUTLOOK THERAPEUTICS's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is expected to rise to 0.21 this year. Enterprise Value Multiple is expected to rise to 0.21 this year. Fundamental drivers impacting OUTLOOK THERAPEUTICS's valuation include:
Price Book 10.1912 | Enterprise Value 48.2 M | Enterprise Value Ebitda (4.13) | Price Sales 13.2716 | Forward PE 2.8498 |
Undervalued
Today
Please note that OUTLOOK THERAPEUTICS's price fluctuation is extremely dangerous at this time. Calculation of the real value of OUTLOOK THERAPEUTICS INC is based on 3 months time horizon. Increasing OUTLOOK THERAPEUTICS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
OUTLOOK THERAPEUTICS's intrinsic value may or may not be the same as its current market price of 2.01, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.01 | Real 2.42 | Target 3.75 | Hype 1.88 |
The intrinsic value of OUTLOOK THERAPEUTICS's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence OUTLOOK THERAPEUTICS's stock price.
Estimating the potential upside or downside of OUTLOOK THERAPEUTICS INC helps investors to forecast how OUTLOOK stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of OUTLOOK THERAPEUTICS more accurately as focusing exclusively on OUTLOOK THERAPEUTICS's fundamentals will not take into account other important factors: OUTLOOK THERAPEUTICS INC Company Current Valuation Analysis
OUTLOOK THERAPEUTICS's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current OUTLOOK THERAPEUTICS Current Valuation | 48.25 M |
Most of OUTLOOK THERAPEUTICS's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OUTLOOK THERAPEUTICS INC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
OUTLOOK Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for OUTLOOK THERAPEUTICS is extremely important. It helps to project a fair market value of OUTLOOK Stock properly, considering its historical fundamentals such as Current Valuation. Since OUTLOOK THERAPEUTICS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OUTLOOK THERAPEUTICS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OUTLOOK THERAPEUTICS's interrelated accounts and indicators.
Click cells to compare fundamentals
OUTLOOK Current Valuation Historical Pattern
Today, most investors in OUTLOOK THERAPEUTICS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various OUTLOOK THERAPEUTICS's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of OUTLOOK THERAPEUTICS current valuation as a starting point in their analysis.
OUTLOOK THERAPEUTICS Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, OUTLOOK THERAPEUTICS INC has a Current Valuation of 48.25 M. This is 99.66% lower than that of the Biotechnology sector and 98.96% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.71% higher than that of the company.
OUTLOOK Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OUTLOOK THERAPEUTICS's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OUTLOOK THERAPEUTICS could also be used in its relative valuation, which is a method of valuing OUTLOOK THERAPEUTICS by comparing valuation metrics of similar companies.OUTLOOK THERAPEUTICS is currently under evaluation in current valuation category among its peers.
OUTLOOK THERAPEUTICS Current Valuation Drivers
We derive many important indicators used in calculating different scores of OUTLOOK THERAPEUTICS from analyzing OUTLOOK THERAPEUTICS's financial statements. These drivers represent accounts that assess OUTLOOK THERAPEUTICS's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of OUTLOOK THERAPEUTICS's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 52.2M | 331.3M | 258.7M | 55.3M | 49.8M | 91.1M | |
| Enterprise Value | 48.5M | 328.7M | 252.3M | 67.5M | 60.7M | 97.1M |
OUTLOOK THERAPEUTICS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, OUTLOOK THERAPEUTICS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to OUTLOOK THERAPEUTICS's managers, analysts, and investors.Environmental | Governance | Social |
OUTLOOK Fundamentals
| Return On Equity | -0.0365 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | 48.25 M | ||||
| Shares Outstanding | 23.66 M | ||||
| Shares Owned By Insiders | 35.58 % | ||||
| Shares Owned By Institutions | 35.63 % | ||||
| Number Of Shares Shorted | 3.51 M | ||||
| Price To Earning | (1.24) X | ||||
| Price To Book | 10.19 X | ||||
| Price To Sales | 13.27 X | ||||
| Revenue | 5.85 M | ||||
| Gross Profit | (42.33 M) | ||||
| EBITDA | (71.7 T) | ||||
| Net Income | (75.37 T) | ||||
| Cash And Equivalents | 26.02 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 297.83 B | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | (3.58) X | ||||
| Cash Flow From Operations | (68.79 T) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (4.06) X | ||||
| Target Price | 24.8 | ||||
| Number Of Employees | 24 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 47.55 M | ||||
| Total Asset | 28.82 T | ||||
| Retained Earnings | (543.28 T) | ||||
| Working Capital | (15.75 M) | ||||
| Current Asset | 4.12 M | ||||
| Current Liabilities | 28.27 M | ||||
| Net Asset | 28.82 T |
About OUTLOOK THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OUTLOOK THERAPEUTICS INC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OUTLOOK THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OUTLOOK THERAPEUTICS INC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out OUTLOOK THERAPEUTICS Piotroski F Score and OUTLOOK THERAPEUTICS Altman Z Score analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.